SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1543)4/19/1998 10:24:00 PM
From: Maurice Winn  Read Replies (1) of 1762
 
Okay, so we can use CHOP to really give the NHLs a fright. Then some Oncolym to sort out the men from the boys. Meanwhile some TNT and antiangiogenesis to wreck tumors from the inside out. Then, [there not being enough somatic variations left to form a quorum] the remnants could be dentritic-celled into complete submission.

With that onslaught, I wouldn't fancy my chances if I was an NHL cell cowering in some lyph node tucked away in a toenail...

That doesn't include a bit of Rituxan or Bexxar which would perhaps be called up as reinforcements after the initial CHOP. I'd have thought that combination attachments to CD20 and the hooks which Oncolym and Bexxar use would be the way to really make a mess of NHLs.

The pursuit via somatic variant matching seems less difficult with the advent of Affymetrix type equipment. In the end, using our own immune systems seems the most cunning approach. [or course better still would be genetic selection for no cancer in the first place but that isn't much help to those of us stuck with the pathetic little gene pool donated by our randomly mated parents].

Just some thoughts as a layman.
Thanks for the reference and expert comment.

Maurice
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext